I am seeing a more rapid enrolment of clients. I would say we're not yet at the point where there are many clinical trials—phase one, phase two, phase three—but we're more into the trials of testing. There are few Canadian studies I'm aware of that are currently under way in randomized controlled trials with interventions that would look at vaccine-like status or serum conversion. There is much more testing going on, and I'd like us to go even further than that.
Yes, it has been easy, for example, in my own institution, with our own research ethics board. There's something called the Respect study, looking at the uptake of the disease and the disease in health care workers, and very rapid movement through an REB, very rapid deployment, very rapid enrolment, very rapid engagement of the laboratory system for testing.
One of the challenges I do believe we have at the moment, particularly for randomized control trials, is access to supplies, so again swabs and reagents. There are usually, with RCTs, significant amounts of laboratory testing and data collection, and there is a yin and yang or a bit of worry at the moment whether we have enough for our clinical needs so that we don't allow our research need to take it away from Canadians who need the test for clinical purposes.
Increasingly, we're trying to look at the overlap, where those who need the test for clinical purposes can also be enrolled in research studies, with their consent.